Compounds > alpha-aminopyridine
Page last updated: 2024-08-21

alpha-aminopyridine and Cognition Disorders

alpha-aminopyridine has been researched along with Cognition Disorders in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's6 (66.67)24.3611
2020's1 (11.11)2.80

Authors

AuthorsStudies
Johe, K; Lee, Y; McIntyre, RS; Rong, C1
Bormans, G; Bruffaerts, R; Dries, E; Dupont, P; Evenepoel, C; Gabel, S; Koole, M; Liuzzi, AG; Meersmans, K; Peeters, R; Pijnenburg, Y; Schaeverbeke, J; Sieben, A; Van Bouwel, K; Van Laere, K; Vandenberghe, R1
Davison, C; Farah, Y; Gilleen, J; Kerins, S; Lahu, G; Mehta, MA; Ogrinc, F; Reichenberg, A; Shergill, SS; Tsai, M; Uz, T; Valdearenas, L; Williams, SC1
Fu, T; Guo, L; Huang, P; Li, C; Lu, Q; Xu, X; Yi, Z; Zhao, D1
Farde, L; Forsberg, A; Halldin, C; Mattsson, P; Nilsson, LG; Nyberg, L; Persson, J1
Arora, RP; Green, KN; Hernandez, MX; Lee, RJ; Rice, RA; Spangenberg, EE; Tenner, AJ; West, BL; Yamate-Morgan, H1
Girish, R; Jabaris, SS; Narayanan, S; Saravana Babu, C; Sugumar, M; Sumathy, H; Thanikachalam, M; Thanikachalam, S1
Abraham, WM; Claveau, D; Dias, R; Dubé, D; Gallant, M; Girard, Y; Goetghebeur, P; Huang, Z; Jones, T; Lacombe, P; Laliberte, F; Liu, S; Macdonald, D; Mancini, JA; Ng, K; Nicholson, DW; Otu, F; Styhler, A; Turner, MJ; Young, RN; Zhang, L1
Akahane, A; Aoki, S; Iwashita, A; Matsuda, R; Matsuoka, N; Mihara, K; Mihara, T; Mitani, Y; Yamamoto, H; Yarimizu, J1

Reviews

1 review(s) available for alpha-aminopyridine and Cognition Disorders

ArticleYear
The neurogenic compound, NSI-189 phosphate: a novel multi-domain treatment capable of pro-cognitive and antidepressant effects.
    Expert opinion on investigational drugs, 2017, Volume: 26, Issue:6

    Topics: Adult; Aminopyridines; Animals; Antidepressive Agents; Bipolar Disorder; Cognition; Cognition Disorders; Depressive Disorder, Major; Hippocampus; Humans; Neurogenesis; Piperazines

2017

Trials

1 trial(s) available for alpha-aminopyridine and Cognition Disorders

ArticleYear
An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients.
    Psychopharmacology, 2021, Volume: 238, Issue:5

    Topics: Adult; Aminopyridines; Animals; Benzamides; Brain; Cognition; Cognition Disorders; Cross-Over Studies; Cyclopropanes; Double-Blind Method; Female; Humans; Male; Memory, Episodic; Memory, Short-Term; Middle Aged; Phosphodiesterase 4 Inhibitors; Prefrontal Cortex; Schizophrenia

2021

Other Studies

7 other study(ies) available for alpha-aminopyridine and Cognition Disorders

ArticleYear
Single-word comprehension deficits in the nonfluent variant of primary progressive aphasia.
    Alzheimer's research & therapy, 2018, 07-18, Volume: 10, Issue:1

    Topics: Aged; Aged, 80 and over; Aminopyridines; Amyloid beta-Peptides; Aniline Compounds; Aphasia, Primary Progressive; Brain; Cognition Disorders; Comprehension; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Positron-Emission Tomography; Quinolines; Thiazoles; Tomography Scanners, X-Ray Computed; Vocabulary

2018
Flupirtine attenuates chronic restraint stress-induced cognitive deficits and hippocampal apoptosis in male mice.
    Behavioural brain research, 2015, Jul-15, Volume: 288

    Topics: Aminopyridines; Animals; Apoptosis; Chronic Disease; Cognition Disorders; Dendritic Spines; Disease Models, Animal; Hippocampus; Male; Maze Learning; Mice; Neurons; Neuroprotective Agents; Nootropic Agents; Random Allocation; Restraint, Physical; Spatial Memory; Stress, Psychological

2015
β-Amyloid binding in elderly subjects with declining or stable episodic memory function measured with PET and [¹¹C]AZD2184.
    European journal of nuclear medicine and molecular imaging, 2015, Volume: 42, Issue:10

    Topics: Aged; Aminopyridines; Amyloid beta-Peptides; Benzothiazoles; Carbon Radioisotopes; Cognition Disorders; Female; Humans; Male; Memory Disorders; Memory, Episodic; Middle Aged; Molecular Imaging; Positron-Emission Tomography; Protein Binding; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity

2015
Elimination of Microglia Improves Functional Outcomes Following Extensive Neuronal Loss in the Hippocampus.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2015, Jul-08, Volume: 35, Issue:27

    Topics: Aminopyridines; Animals; Behavioral Symptoms; Blood-Brain Barrier; Brain Injuries; Cognition Disorders; Dendritic Spines; Disease Models, Animal; Doxycycline; Female; Hippocampus; Male; Maze Learning; Mice; Mice, Transgenic; Microglia; Neurons; Phosphopyruvate Hydratase; Pyrroles; Recovery of Function; Synaptophysin

2015
Phosphodiesterase-4 inhibitors ameliorates cognitive deficits in deoxycorticosterone acetate induced hypertensive rats via cAMP/CREB signaling system.
    Brain research, 2015, Oct-05, Volume: 1622

    Topics: Adrenergic alpha-2 Receptor Agonists; Aminopyridines; Animals; Antihypertensive Agents; Benzamides; Brain-Derived Neurotrophic Factor; Clonidine; Cognition Disorders; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclopropanes; Desoxycorticosterone Acetate; Disease Models, Animal; Hippocampus; Hypertension; Male; Memory; Nootropic Agents; Phosphodiesterase 4 Inhibitors; Rats; Rats, Wistar; Rolipram

2015
L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
    Biochemical pharmacology, 2007, Jun-15, Volume: 73, Issue:12

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Animals; Apoenzymes; Ascaris suum; Asthma; Benzamides; Bronchoconstriction; Carboxylic Acids; Cognition Disorders; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Guinea Pigs; Humans; Inhibitory Concentration 50; Injections, Intraperitoneal; Interferon-gamma; Male; Molecular Structure; Nitriles; Ovalbumin; Polymerase Chain Reaction; Quinolines; Rats; Sensitivity and Specificity; Sheep

2007
Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.
    The Journal of pharmacology and experimental therapeutics, 2007, Volume: 323, Issue:2

    Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Aminopyridines; Animals; CHO Cells; Cognition Disorders; Cricetinae; Cricetulus; Dopamine; Haloperidol; Humans; Male; Memory Disorders; Mice; Mice, Inbred C57BL; MPTP Poisoning; Phenethylamines; Piperazines; Rats; Rats, Inbred F344; Rats, Wistar; Receptor, Adenosine A1; Receptor, Adenosine A2A; Scopolamine

2007